Aquatic Capital Management LLC Purchases New Stake in Hims & Hers Health, Inc. $HIMS

Aquatic Capital Management LLC acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 92,257 shares of the company’s stock, valued at approximately $5,233,000.

Several other institutional investors have also recently added to or reduced their stakes in HIMS. Pathway Capital Management LP bought a new position in Hims & Hers Health in the third quarter worth about $6,766,000. Steadview Capital Management LLC grew its holdings in shares of Hims & Hers Health by 80.0% during the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after purchasing an additional 311,845 shares during the last quarter. State of Michigan Retirement System lifted its holdings in shares of Hims & Hers Health by 49.2% in the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after purchasing an additional 678,600 shares during the last quarter. Carnegie Investment Counsel lifted its holdings in shares of Hims & Hers Health by 25.4% in the 3rd quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock worth $17,238,000 after purchasing an additional 61,560 shares during the last quarter. Finally, BIT Capital GmbH lifted its holdings in shares of Hims & Hers Health by 73.8% in the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after purchasing an additional 938,728 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 0.9%

Hims & Hers Health stock opened at $24.99 on Tuesday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The stock has a market capitalization of $5.70 billion, a PE ratio of 49.00, a price-to-earnings-growth ratio of 2.34 and a beta of 2.56. The firm has a 50 day simple moving average of $23.64 and a 200-day simple moving average of $37.20.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The firm had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.11 earnings per share. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has approved a share repurchase program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In related news, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at $11,202,460.31. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the sale, the insider owned 2,126 shares in the company, valued at approximately $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 80,463 shares of company stock valued at $2,846,696. 17.71% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. TD Cowen lowered their price objective on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research note on Tuesday, February 24th. Barclays raised their target price on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Needham & Company LLC upgraded shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Monday, March 9th. Bank of America raised shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and increased their price objective for the stock from $12.50 to $23.00 in a report on Tuesday, March 10th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, March 10th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $31.29.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.